Market Access 2020: Understanding US Payer Expectations

Paying for Pharmaceutical Value: The Problem of a One-Size-Fits-All Definition

Are Payers Ready, Willing, and Able to Provide Access to New Durable Gene Therapies?

Examining New Payment Ideas for Curative Therapies

AstraZeneca strikes a ‘novel’ deal with Medicare plan to lower patient out-of-pocket costs

What rebates? Express Scripts touts a new plan to appease critics of the opaque drug-pricing system

Backing into Value with Part B

Teva Stands By Migraine Strategy After Ajovy Misses Boat On Express Scripts Deal

Defining access potential – Before it’s too late

Depression Rising (Again): Turning the Corner in Psychiatry’s Most Burdensome Disorder